T M Churilla1, E Handorf1, S Collette2, L Collette2, Y Dong1, A A Aizer3, M Kocher4, R Soffietti5, B M Alexander3, S E Weiss6. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA. 2. EORTC Headquarters, Brussels, Belgium. 3. Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, USA. 4. Department of Radiation Oncology, University of Cologne, Cologne, Germany. 5. Department of Neuro-oncology, University of Turin and City of Health and Science Hospital, Torino, Italy. 6. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA;. Electronic address: stephanie.weiss@fccc.edu.
Abstract
BACKGROUND: The absence of a survival benefit for whole brain radiotherapy (WBRT) among randomized trials has been attributed to a competing risk of death from extracranial disease. We re-analyzed EORTC 22952 to assess the impact of WBRT on survival for patients with controlled extracranial disease or favorable prognoses. PATIENTS AND METHODS: We utilized Cox regression, landmark analysis, and the Kaplan-Meier method to evaluate the impact of WBRT on survival accounting for (i) extracranial progression as a time-dependent covariate in all patients and (ii) diagnosis-specific graded prognostic assessment (GPA) score in patients with primary non-small-cell lung cancer (NSCLC). RESULTS: A total of 329 patients treated per-protocol were included for analysis with a median follow up of 26 months. One hundred and fifteen (35%) patients had no extracranial progression; 70 (21%) patients had progression <90 days, 65 (20%) between 90 and 180 days, and 79 (24%) patients >180 days from randomization. There was no difference in the model-based risk of death in the WBRT group before [hazard ratio (HR) (95% CI)=0.70 (0.45-1.11), P = 0.133), or after [HR (95% CI)=1.20 (0.89-1.61), P = 0.214] extracranial progression. Among 177 patients with NSCLC, 175 had data available for GPA calculation. There was no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores [HR (95% CI)=1.10 (0.68-1.79)] or unfavorable GPA scores [HR (95% CI)=1.11 (0.71-1.76)]. CONCLUSIONS: Among patients with limited extracranial disease and one to three brain metastases at enrollment, we found no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores or patients with any histology and controlled extracranial disease status. This exploratory analysis of phase III data supports the practice of omitting WBRT for patients with limited brain metastases undergoing SRS and close surveillance. CLINICAL TRIALS NUMBER: NCT00002899.
BACKGROUND: The absence of a survival benefit for whole brain radiotherapy (WBRT) among randomized trials has been attributed to a competing risk of death from extracranial disease. We re-analyzed EORTC 22952 to assess the impact of WBRT on survival for patients with controlled extracranial disease or favorable prognoses. PATIENTS AND METHODS: We utilized Cox regression, landmark analysis, and the Kaplan-Meier method to evaluate the impact of WBRT on survival accounting for (i) extracranial progression as a time-dependent covariate in all patients and (ii) diagnosis-specific graded prognostic assessment (GPA) score in patients with primary non-small-cell lung cancer (NSCLC). RESULTS: A total of 329 patients treated per-protocol were included for analysis with a median follow up of 26 months. One hundred and fifteen (35%) patients had no extracranial progression; 70 (21%) patients had progression <90 days, 65 (20%) between 90 and 180 days, and 79 (24%) patients >180 days from randomization. There was no difference in the model-based risk of death in the WBRT group before [hazard ratio (HR) (95% CI)=0.70 (0.45-1.11), P = 0.133), or after [HR (95% CI)=1.20 (0.89-1.61), P = 0.214] extracranial progression. Among 177 patients with NSCLC, 175 had data available for GPA calculation. There was no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores [HR (95% CI)=1.10 (0.68-1.79)] or unfavorable GPA scores [HR (95% CI)=1.11 (0.71-1.76)]. CONCLUSIONS: Among patients with limited extracranial disease and one to three brain metastases at enrollment, we found no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores or patients with any histology and controlled extracranial disease status. This exploratory analysis of phase III data supports the practice of omitting WBRT for patients with limited brain metastases undergoing SRS and close surveillance. CLINICAL TRIALS NUMBER: NCT00002899.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: T C van der Ree; D W Dippel; C J Avezaat; P A Sillevis Smitt; C J Vecht; M J van den Bent Journal: J Neurol Neurosurg Psychiatry Date: 1999-02 Impact factor: 10.154
Authors: L Gaspar; C Scott; M Rotman; S Asbell; T Phillips; T Wasserman; W G McKenna; R Byhardt Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Thomas M Churilla; Karla V Ballman; Paul D Brown; Erin L Twohy; Kurt Jaeckle; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Yolanda I Garces; Fred G Barker; Richard Deming; Jesse G Dixon; Stuart H Burri; Caroline Chung; Cynthia Ménard; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-05 Impact factor: 7.038
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: J Clin Oncol Date: 2020-09-15 Impact factor: 44.544
Authors: Paul W Sperduto; Brian De; Jing Li; David Carpenter; John Kirkpatrick; Michael Milligan; Helen A Shih; Tugce Kutuk; Rupesh Kotecha; Hajime Higaki; Manami Otsuka; Hidefumi Aoyama; Malie Bourgoin; David Roberge; Salah Dajani; Sean Sachdev; Jordan Gainey; John M Buatti; William Breen; Paul D Brown; Lisa Ni; Steve Braunstein; Matthew Gallitto; Tony J C Wang; Ryan Shanley; Emil Lou; Jay Shiao; Laurie E Gaspar; Satoshi Tanabe; Toshimichi Nakano; Yi An; Veronica Chiang; Liang Zeng; Hany Soliman; Hesham Elhalawani; Daniel Cagney; Evan Thomas; Drexell H Boggs; Manmeet S Ahluwalia; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2022-03-21 Impact factor: 8.013
Authors: Pantelis Stavrinou; Lars Plambeck; Martin Proescholdt; Markus Ghadimi; Roland Goldbrunner; Stefan Grau Journal: Medicine (Baltimore) Date: 2019-08 Impact factor: 1.889
Authors: Margarita Martin; Raúl Hernanz; Carmen Vallejo; Leonardo Guerrero; Xabier Mielgo; Ana Lopez; Juan Carlos Trujillo-Reyes; Felipe Couñago Journal: Rep Pract Oncol Radiother Date: 2022-07-29
Authors: Dianne Hartgerink; Britt van der Heijden; Dirk De Ruysscher; Alida Postma; Linda Ackermans; Ann Hoeben; Monique Anten; Philippe Lambin; Karin Terhaag; Arthur Jochems; Andre Dekker; Janna Schoenmaekers; Lizza Hendriks; Jaap Zindler Journal: Front Oncol Date: 2018-05-09 Impact factor: 6.244